ID: MRFR/HC/5599-HCR | February 2021 | Region: Global | 90 pages
Fabry Disease Market Scenario
Fabry disease market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 794.6 million in 2017 and is projected to grow at a CAGR of 6.8% over the forecast period.
Fabry disease is a rare inherited disorder that occurs due to building-up of globotriaosylceramide in the body's cells. The disease affects both men and women, but men are usually more severely affected. According to the recent data suggested by the National Institute of Health, Fabry disease affects an nearly 1 in 40,000 to 60,000 males.
Extensive research and development activities is one of the key factors driving the Fabry disease market. On May 30, 2018, Amicus Therapeutics launched Galafold capsules 123mg for the treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. It is also reported that Galafold is the first and only oral precision medicine for Fabry disease in Japan. Apart from this there are many treatment approaches are under clinical trials for the treatment of Fabry disease. For instance, Pegunigalsidase alfa by Protalix is under phase-3 clinical trial for the treatment of patients affected with Fabry disease.
Various other factors such as technological advancements, developing healthcare infrastructure, and favourable reimbursement and funding policies in developed countries are also expected to propel the growth of the market.
However, the lack of awareness of the disease among physicians in developing or underdeveloped countries, diverse range of symptoms, and other complications can hinder the market growth over the forecast period.
The global Fabry disease market has been segmented into type, diagnosis & treatment and end user.
The market, based on type, has been segmented into type-1 and type-2.
The market, by diagnosis & treatment, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as blood test, urine test, thyroid test, lung function test, and imaging. The imaging segment includes electrocardiogram (EKG), echocardiogram, brain MRI, CT scan and others. The treatment segment is further classified as enzyme replacement therapy, gene therapy, pharmaceutical formulations containing agalsidase alfa, analgesics, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), and others.
The market, by end user, has been segmented into hospitals & clinics, diagnostic centres, research & academic institutes, and others.
The enzyme replacement therapy is anticipated to hold the largest market share as it is the most preferred therapeutic approach to stabilize the progression of the Fabry disease.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Fabry disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Fabry Disease market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Fabry Disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Fabry Disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Amgen Inc., Amicus Therapeutics, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and others are some of the key players in the global Fabry disease market.
Regional Market Summary
Fabry Disease Global Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the global Fabry disease market owing to rising healthcare expenditure, increasing awareness about the condition and technological advancements in Fabry Disease. According to the National Fabry Disease Foundation, nearly 50,000 people, in the United States, are living with Fabry disease.
Europe is expected to hold the second largest position in the global Fabry disease market. The market growth in this region is attributed to the government funding and improvement in research & development activities. In European region, Replagal by Shire is one of the most preferred treatment approaches. The approved dose of Replagal is 0.2 milligrams per kilogram of body weight.
The Fabry disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing awareness about the enzyme replacement therapy and rising healthcare spending. According to the 2016 data suggested by the Ministry of Health and Family Welfare, approximate annual cost of enzyme replacement therapy in India was USD 26,334.
The Middle East & Africa are expected to hold the least share of the market due to lack of awareness about the condition.
Global Fabry Disease Market, by Type:
Global Fabry Disease Market, by Diagnosis & Treatment:
Global Fabry Disease Market, by End User:
Global Fabry Disease Market, by Region:
Global Fabry Disease Market, by Key Players:
Frequently Asked Questions (FAQ) :
The fabry disease market was valued at USD 794.6 million in 2017.
The fabry disease market has the potential to grow with 6.8% CAGR during the forecast period of 2018 to 2023.
The fabry disease market has extensive research and development facilities which could bolster its growth.
The leading treatment therapy segment is an enzyme replacement therapy for the fabry disease market.
The Americas has the potential to score the highest for the fabry disease market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.